Table 2 Comparison of demographic and clinical characteristics of the patients with endoscopically quiescent ulcerative colitis with bowel symptoms with those without bowel symptoms
|  | UC patients with bowel symptoms (n = 244) | UC patients without bowel symptoms (n = 497) | P value |
|---|---|---|---|
Total patient-years of follow-up (years) | 2970.6 | 5904.7 | 0.489* |
Median (IQR) (years) | 11.6 (6.3–15.4) | 10.8 (6.3–15.4) |  |
Demographic features | Â | Â | Â |
Age at diagnosis of UC, median (IQR) (years) | 41 (31–52) | 41 (32–51) | 0.680* |
Sex, female, n (%) | 101 (41.4) | 242 (48.7) | 0.061** |
Family history of IBD, n (%) | 22 (9.0) | 46 (9.3) | 0.916** |
History of appendectomy, n (%) | 6 (2.5) | 14 (2.8) | 0.778** |
Current or ex-smoker, n (%) | 90 (36.9) | 209 (42.1) | 0.178** |
Extraintestinal manifestation, n (%) | 4 (1.6) | 17 (3.4) | 0.170** |
PSC, n (%) | 3 (1.2) | 6 (1.2) | 1.000*** |
Maximum extent of UC | Â | Â | 0.002*** |
Proctitis (E1), n (%) | 44 (18.0) | 153 (30.8) | Â |
Left-sided colitis (E2), n (%)` | 86 (35.2) | 154 (31.0) | Â |
Extensive colitis (E3), n (%) | 108 (44.3) | 182 (36.6) | Â |
Not enough data, n (%) | 6 (2.5) | 8 (1.6) | Â |
History of immunosuppressive drug use for UC, n (%) | Â | Â | Â |
CS (prednisolone or methylprednisolone), n (%) | 160 (65.6) | 263 (52.9) | < 0.001** |
IS (azathiopurine/6-mercaptopurine, methotrexate, cyclosporine, or tacrolimus), n (%) | 75 (30.7) | 116 (23.3) | 0.030** |
Biologics (infliximab, adalimumab, golimumab, or vedolizumab), n (%) | 23 (9.4) | 56 (11.3) | 0.445** |